6VX logo

Healios K.K DB:6VX Stock Report

Last Price

€1.65

Market Cap

€158.2m

7D

-1.2%

1Y

117.1%

Updated

06 Feb, 2025

Data

Company Financials +

Healios K.K.

DB:6VX Stock Report

Market Cap: €158.2m

6VX Stock Overview

Engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. More details

6VX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 39.69% per year

Risk Analysis

Does not have meaningful revenue (¥549M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the German market

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

Healios K.K. Competitors

2invest

XTRA:2INV

€67.8m

Heidelberg Pharma

XTRA:HPHA

€110.5m

Formycon

XTRA:FYB

€965.8m

Biotest

XTRA:BIO3

€1.4b

Price History & Performance

Summary of share price highs, lows and changes for Healios K.K
Historical stock prices
Current Share PriceJP¥1.65
52 Week HighJP¥1.85
52 Week LowJP¥0.66
Beta1.13
1 Month Change57.14%
3 Month Change48.65%
1 Year Change117.11%
3 Year Change-78.45%
5 Year Changen/a
Change since IPO-88.38%

Recent News & Updates

Recent updates

Shareholder Returns

6VXDE BiotechsDE Market
7D-1.2%2.3%0.5%
1Y117.1%-2.6%15.3%

Return vs Industry: 6VX exceeded the German Biotechs industry which returned -4.6% over the past year.

Return vs Market: 6VX exceeded the German Market which returned 13.7% over the past year.

Price Volatility

Is 6VX's price volatile compared to industry and market?
6VX volatility
6VX Average Weekly Movement10.9%
Biotechs Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6VX's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6VX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201164Hardy Kagimotowww.healios.co.jp

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma. It also develops HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration; and HLCN061, which is in discovery and preclinical trial for treating solid tumors.

Healios K.K. Fundamentals Summary

How do Healios K.K's earnings and revenue compare to its market cap?
6VX fundamental statistics
Market cap€158.20m
Earnings (TTM)-€39.53m
Revenue (TTM)€3.49m

45.4x

P/S Ratio

-4.0x

P/E Ratio

Is 6VX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6VX income statement (TTM)
RevenueJP¥549.00m
Cost of RevenueJP¥98.00m
Gross ProfitJP¥451.00m
Other ExpensesJP¥6.67b
Earnings-JP¥6.22b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 14, 2025

Earnings per share (EPS)-68.97
Gross Margin82.15%
Net Profit Margin-1,133.33%
Debt/Equity Ratio117.8%

How did 6VX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 18:34
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Healios K.K. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hidemaru YamaguchiCitigroup Inc
Akinori UedaGoldman Sachs
Stephen BarkerJefferies LLC